Correspondence to: richard.gaynor@biontech.us (R.B.G.), lakshmi.srinivasan1@external.biontech.us (L.S.) SUMMARY 摘要 Neoantigens arising from mutations in tumor DNA provide targets for immune-based therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a p...
,lakshmi.srinivasan1@external.biontech.us (L.S.)In briefIn a Phase Ib clinical study, Awad et al.demonstrate feasibility, safety, andimmunogenicity of NEO-PV-01 pluschemotherapy and PD-1 inhibition inadvanced NSCLC as a f i rst-line treat-ment. Neoantigen-specif i c CD4 + T cellshave ...